Caris Life Sciences Secures $168M in New Funding, Bringing Total Capital Raised to Over $1.86B Ahead of IPO

Registration: First Global Ophthalmology Conference | Agenda Update

Registration: First Global Orthopedics Conference | Agenda Update

Registration: First Global Cardiovascular Conference| Award Application

Call for Partners: 2025 Global Surgical Robotics Conference

Recently, Caris Life Sciences, a life sciences company, announced that it has completed a round$168 million (approximately 1.22 billion RMB)'s financing to support the development of its precision medicine platform.

This financing was led by investor Braidwell, with participation from Perceptive Advisors, Woodline, Ghisallo, Millennium Management, and First Light Asset Management. This round of financing brings Caris Life Sciences' total funding since 2018 to$1.86 billion (approximately 13.598 billion RMB)

# Core Business

Caris Life Sciences was founded in 2008.The company is committed to providing precise diagnosis and treatment solutions for cancer and other complex disease patients through molecular analysis and artificial intelligence technology.

• Physician Tests Business
  

Including tissue analysis, blood analysis, and artificial intelligence-related services.

• Molecular Analysis Technology:MI Profile™，Used to evaluate DNA, RNA, and proteins in tumor tissues, assistingGuide precise and personalized treatment decisions. Including next-generation sequencing (NGS) products, such asMI Cancer Seek™ (Companion Diagnostic Reagent),MI Tumor Seek Hybrid™ (Laboratory Developed Test), etc.

  Among them,MI Cancer Seek^® YesThe first and only detection method that combines whole exome sequencing (WES) and whole transcriptome sequencing (WTS) simultaneously., has received U.S. FDA approval for companion diagnostic (CDx) indications in solid tumor molecular profiling.

  

• Blood Analysis:Caris Assure™ It is a minimally invasive blood test.This is a new type of liquid biopsy method,Can be used to detect somatic tumor mutations, etc.

• Artificial Intelligence Algorithm Products:For example,Caris GPSai™ The algorithm can analyze genomic and transcriptomic data, matching the molecular characteristics of tumors with 90 cancer categories in the database, aiding in the management of Cancer of Unknown Primary (CUP) cases, etc.

  Caris FOLFIRSTai™ YesThe FirstA clinically validated, AI-based molecular prediction tool for chemotherapy efficacy, specifically designed for patients with metastatic colorectal cancer (mCRC).

• Physician Services Business

Right-In-Time Clinical Trial Network：Collaborate with trial sites to develop, review, and submit the required regulatory documents and documentation.

# Launch Strategic Cooperation

January 2025,Caris Life Sciences Announcement with Ontada^®Establish a strategic partnership.Ontada^®Is an enterprise focused on real-world evidence in oncology, clinical education, and medical technology.

This collaboration will leverage Caris's extensive molecular data and multimodal database, which is derived from over6.5 million timesTesting, generated over13,000 trillionData points, as well as Ontada real-world oncology data, which coverMore than 2.4 millionMedical records of cancer patients, which can be used for researchOver 80Tumor TypeTumor type.

Previously, the company had already established partnerships with multiple enterprises,Including andReal-World Data Analysis Company in OncologyCOTAReach cooperation;Announcement of Cooperation withAbbVieEstablished multi-year cooperative relationships to support AbbVie's precision medicine research and development efforts in the field of oncology, as well as clinical trial optimization; and formed a multi-year strategic partnership with biotechnology company Flare Therapeutics, among others.

Among them, it is worth noting that, in April 2024,Caris Life SciencesCaris Discovery™, the treatment research division, announces partnership withMerck KGaA, Darmstadt, GermanyEstablish a multi-year strategic partnership to accelerate the discovery and development for cancer patientsPioneering Antibody-Drug Conjugates (ADC).

The collaboration includes an upfront payment and research funding from Merck to Caris, with Caris eligible to receive up to $1.4 billion in discovery, development, regulatory, and sales milestone payments, as well as tiered royalties. Merck will obtain the global exclusive license for the development, manufacturing, and commercialization of specific-target ADC therapeutics.

# AboutCaris Life Sciences